Roche's New Weight Loss Pill Shakes Up Pharmaceutical Market

Early trial results from Roche's CT-996 pill show significant weight loss, impacting shares of competitors Eli Lilly and Novo Nordisk.

Roche's CT-996 pill demonstrated a 6.1% placebo-adjusted weight loss in a Phase 1 trial.
Shares of Roche rose by over 5%, while Eli Lilly and Novo Nordisk stocks fell by approximately 3% and 4%, respectively.
The new pill offers a once-daily oral alternative to existing injectable GLP-1 drugs.
Roche acquired the CT-996 drug through its purchase of Carmot Therapeutics in January.
The weight loss drug market is anticipated to reach $150 billion by the early 2030s.